Bracco Diagnostics Inc. Branded Max 3™, a Rapid Exchange and Syringeless Injector, received FDA 510(k) clearance adding evolving innovation in Magnetic Resonance Imaging (MRI) and its product portfolio

PRINCETON, N.J., Dec. 2, 2024 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, along with ulrich GmbH & Co. KG, a renowned German medical device manufacturer specializing in contrast media injectors and spinal implants, announced today the clearance of the Bracco branded Max 3™, a Rapid Exchange and Syringeless Injector for use in magnetic resonance imaging (MRI) procedures.

The Max 3 is a first of its kind in the MRI space. The innovative injector offers intuitive, efficient, and easy-to-manage features such as direct injection from original contrast media vials meaning no need for refilling of syringes, and no power cables so it can be positioned anywhere in the MRI room up to a maximum magnetic field strength of 50mT. The Easy-Click-Cassette flex has a dedicated connector to the patient tubing with SafeConnect, providing contact protection and reliable protection against retrograde contamination which can be used within 24 hours or up to a maximum of 96 bottles of contrast media, or whichever comes first, thus improving workflow for the technologist, allowing more time to focus on the patient during a procedure.

In addition to being easy to use, the Max 3 injector supports best practices in radiology sustainability. This injector will strengthen green efforts in radiology suites because it will contribute less plastic to a hospital’s disposable process and costs.

Sign up for Blog Updates